LHI0.F Algorae Pharmaceuticals Limited
- Market cap
- EUR 7.10M
- P/E
- -
- P/B
- 2.31x
- ROE
- -63.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is LHI0.F undervalued?
Graham numberThe Graham number of Algorae Pharmaceuticals Limited cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Algorae Pharmaceuticals Limited fundamental analysis
No fundamental analysis for Algorae Pharmaceuticals Limited yet.
Algorae Pharmaceuticals Limited stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingr…
Full company profileAlgorae Pharmaceuticals Limited financial statements
Algorae Pharmaceuticals Limited annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2026 |
|---|---|---|---|---|
| Income Statement | ||||
| Operating Income | -2.38M | -2.13M | -2.20M | -3.14M |
| EBITDA | -2.38M | -2.13M | -2.20M | -3.07M |
| Net Income | -1.96M | -2.11M | -2.10M | -2.71M |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||
| Total Assets | 7.27M | 6.23M | 5.49M | 4.44M |
| Total Liabilities | 282K | 450K | 178K | 177K |
| Shareholders' Equity | 4.03M | 3.76M | 3.01M | 4.26M |
| Cash & Short-term Investments | 7.24M | 6.13M | 3.11M | 3.19M |
| Cash Flow | ||||
| Capital Expenditure | 3.80K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -2.05M | -1.99M | -1.52M | -2.60M |
| Ratios | ||||
| ROE | -48.5% | -56.0% | -69.5% | -63.6% |
| ROA | -26.9% | -33.8% | -38.2% | -61.1% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Algorae Pharmaceuticals Limited dividends
Algorae Pharmaceuticals Limited has not paid dividends in the last 5 fiscal years.
Who owns Algorae Pharmaceuticals Limited
- Insiders 35.30%
- Institutions 0.00%
- Public & others 64.71%
- Shares outstanding 2.03B
- Free float 1.47B
Algorae Pharmaceuticals Limited company profile
- Company name
- Algorae Pharmaceuticals Limited
- Ticker
- LHI0.F
- ISIN
- AU0000296022
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- Rialto South Tower, Melbourne, VIC, Australia, 3000
- Phone
- 61 2 9698 5414
- Website
- algoraepharma.com
About Algorae Pharmaceuticals Limited
Algorae Pharmaceuticals Limited, an AI-enabled pharmaceutical development company, engages in the research and development of living cells technologies primarily in Australia and New Zealand. The company's product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer's disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate coated capsule product for the treatment of Parkinson's disease. It is also developing AlgaraeOS in partnership with the University of New South Wales, a drug discovery platform that uses artificial intelligence protocols and big data analytics for drug discovery and development; and AlgoraeRx, a commercial pharmaceutical division that source generic and specialty medicines from manufacturers. The company was formerly known as Living Cell Technologies Limited and changed its name to Algorae Pharmaceuticals Limited in September 2023. Algorae Pharmaceuticals Limited was founded in 1987 and is based in Melbourne, Australia.
Algorae Pharmaceuticals Limited management
8- Mr. David Richard HainsworthCEO & Executive Chairman · born 1973
- Mr. David GullandCOO & Director
- Mr. Vishal ShahChief Commercial Officer
- Dr. James A. MckennaChief Scientific Officer
- Mr. Waleed ElsayedHead of Sales
- Dr. Carolyn M. Sue A.M., B.S., Ph.D.Member of Medical Advisory Board & Chief Medical Officer of NTCELL · born 1964
- Ms. Catherine EarlieJoint Company Secretary
- Ms. Geraldine HollandJoint Company Secretary